Sinopharm Group Co Stock Current Liabilities
| SHTDFDelisted Stock | USD 2.70 0.00 0.00% |
Sinopharm Group Co fundamentals help investors to digest information that contributes to Sinopharm Group's financial success or failures. It also enables traders to predict the movement of Sinopharm Pink Sheet. The fundamental analysis module provides a way to measure Sinopharm Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sinopharm Group pink sheet.
Sinopharm |
Sinopharm Group Co Company Current Liabilities Analysis
Sinopharm Group's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Sinopharm Group Current Liabilities | 98.25 B |
Most of Sinopharm Group's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinopharm Group Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Sinopharm Group Co has a Current Liabilities of 98.25 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Medical Distribution industry. The current liabilities for all United States stocks is significantly lower than that of the firm.
Sinopharm Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinopharm Group's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sinopharm Group could also be used in its relative valuation, which is a method of valuing Sinopharm Group by comparing valuation metrics of similar companies.Sinopharm Group is currently under evaluation in current liabilities category among its peers.
Sinopharm Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 16.78 B | |||
| Shares Outstanding | 1.34 B | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 51.07 % | |||
| Price To Earning | 5.67 X | |||
| Price To Book | 0.88 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 521.05 B | |||
| Gross Profit | 44.05 B | |||
| EBITDA | 20.76 B | |||
| Net Income | 7.76 B | |||
| Cash And Equivalents | 32.15 B | |||
| Cash Per Share | 10.30 X | |||
| Total Debt | 8.42 B | |||
| Debt To Equity | 0.89 % | |||
| Current Ratio | 1.31 X | |||
| Book Value Per Share | 21.01 X | |||
| Cash Flow From Operations | 9.31 B | |||
| Earnings Per Share | 0.37 X | |||
| Price To Earnings To Growth | 49.02 X | |||
| Number Of Employees | 113.23 K | |||
| Beta | 0.72 | |||
| Market Capitalization | 8.94 B | |||
| Total Asset | 335.41 B | |||
| Retained Earnings | 11.43 B | |||
| Working Capital | 32.26 B | |||
| Current Asset | 130.51 B | |||
| Current Liabilities | 98.25 B | |||
| Z Score | 1.6 | |||
| Annual Yield | 0.05 % | |||
| Five Year Return | 3.09 % | |||
| Net Asset | 335.41 B | |||
| Last Dividend Paid | 0.75 |
About Sinopharm Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sinopharm Group Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinopharm Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinopharm Group Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Sinopharm Pink Sheet
If you are still planning to invest in Sinopharm Group check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sinopharm Group's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| CEOs Directory Screen CEOs from public companies around the world |